A tumorigenic factor interactome connected through tumor suppressor MicroRNA-198 in human pancreatic cancer

Clinical Cancer Research

Volumn 19, Issue 21, 2013, Pages 5901-5913

  Marin Muller, Christian ^a,b   Li, Dali ^a   Bharadwaj, Uddalak ^a   Li, Min ^a   Chen, Changyi ^a   Hodges, Sally E ^a   Fisher, William E ^a   Mo, Qianxing ^c   Hung, Mien Chie ^d,e   Yao, Qizhi ^a,b,c  

^a Michael E DeBakey Department of Surgery   (United States)

^b Department of Molecular Virology and Microbiology ^*  (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESOTHELIN; MICRORNA; MICRORNA 198; OCTAMER TRANSCRIPTION FACTOR 2; TRANSCRIPTION FACTOR PBX1; UNCLASSIFIED DRUG; VALOSIN CONTAINING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CARCINOGENICITY; CONTROLLED STUDY; DOWN REGULATION; GENE CONTROL; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN RNA BINDING; PROTEIN TARGETING; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; UPREGULATION;

ADENOSINE TRIPHOSPHATASES; ANIMALS; APOPTOSIS; AUTOCRINE COMMUNICATION; CARCINOMA, PANCREATIC DUCTAL; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENES, TUMOR SUPPRESSOR; GPI-LINKED PROTEINS; HUMANS; MICE; MICRORNAS; NEOPLASM METASTASIS; NF-KAPPA B; OCTAMER TRANSCRIPTION FACTOR-2; OPEN READING FRAMES; PANCREATIC NEOPLASMS; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; TUMOR BURDEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84887027457     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3776     Document Type: Article

References (37)

1. Hartwell LH, Hopfield JJ, Leibler S, Murray AW. From molecular to modular cell biology. Nature 1999;402:C47-52.
2. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009;16: 498-509.
3. Wang JX, Jiao JQ, Li Q, Long B, Wang K, Liu JP, et al. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin- related protein-1. Nat Med 2011;17: 71-8.
4. Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP, et al. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 2008;47: 1223-32.
5. Tan S, Li R, Ding K, Lobie PE, Zhu T. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. FEBS Lett 2011;585: 2229-34.
6. Zhao JJ, Yang J, Lin J, Yao N, Zhu Y, Zheng J, et al. Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. Childs Nerv Syst 2009;25: 13-20.
7. Muminova ZE, Strong TV, Shaw DR. Characterization of human mesothelin transcripts in ovarian and pancreatic cancer. BMC Cancer 2004;4: 19.
8. Bharadwaj U, Li M, Chen C, Yao Q. Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3. Mol Cancer Res 2008;6: 1755-65.
9. Li M, Bharadwaj U, Zhang R, Zhang S, Mu H, Fisher WE, et al. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther 2008;7: 286-96.
10. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001;7: 3862-8.
11. Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q. Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Carcinogenesis 2011;32: 1013-24.
12. Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q. Mesothelin confers pancreatic cancer cell resistance to TNF-alpha-induced apoptosis through Akt/PI3K/NF-kappaB activation and IL-6/Mcl-1 overexpression. Mol Cancer 2011;10: 106.
13. Friedl EM, Matthias P. Transcriptional activation and repression, two properties of the lymphoid-specific transcription factor Oct-2a. Eur J Biochem 1995;234: 308-16.
14. Azuara-Liceaga E, Sandoval M, Corona M, Gariglio P, Lopez-Bayghen E. The human involucrin gene is transcriptionally repressed through a tissue-specific silencer element recognized by Oct-2. Biochem Biophys Res Commun 2004;318: 361-71.
15. Bargou RC, Leng C, Krappmann D,Emmerich F, Mapara MY,Bommert K, et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996;87: 4340-7.
16. Bendall HH, Scherer DC, Edson CR, Ballard DW, Oltz EM. Transcription factor NF-kappaB regulates inducible Oct-2 gene expression in precursor B lymphocytes. J Biol Chem 1997;272: 28826-8.
17. Theodorou E, Dalembert G, Heffelfinger C, White E, Weissman S, Corcoran L, et al. A high throughput embryonic stem cell screen identifies Oct-2 as a bifunctional regulator of neuronal differentiation. Genes Dev 2009;23: 575-88.
18. Asahara H, Dutta S, Kao HY, Evans RM, Montminy M. Pbx-Hox heterodimers recruit coactivator-corepressor complexes in an isoform- specific manner. Mol Cell Biol 1999;19: 8219-25.
19. Dutta S, Gannon M, Peers B, Wright C, Bonner-Weir S, Montminy M. PDX:PBX complexes are required for normal proliferation of pancreatic cells during development. Proc Natl Acad Sci U S A 2001;98: 1065-70.
20. Shiraishi K, Yamasaki K, Nanba D, Inoue H, Hanakawa Y, Shirakata Y, et al. Pre-B-cell leukemia transcription factor 1 is a major target of promyelocytic leukemia zinc-finger-mediated melanoma cell growth suppression. Oncogene 2007;26: 339-48.
21. Wang Q, Song C, Li CC. Molecular perspectives on p97-VCP: progress in understanding its structure and diverse biological functions. J Struct Biol 2004;146: 44-57.
22. Asai T, Tomita Y, Nakatsuka S, Hoshida Y, Myoui A, Yoshikawa H, et al. VCP (p97) regulates NFkappaB signaling pathway, which is important for metastasis of osteosarcoma cell line. Jpn J Cancer Res 2002;93: 296-304.
23. Yamamoto S, Tomita Y, Hoshida Y, Nagano H, Dono K, Umeshita K, et al. Increased expression of valosin-containing protein (p97) is associated with lymph node metastasis and prognosis of pancreatic ductal adenocarcinoma. Ann Surg Oncol 2004;11: 165-72.
24. Yamamoto S, Tomita Y, Nakamori S, Hoshida Y, Iizuka N, Okami J, et al. Valosin-containing protein (p97) and Ki-67 expression is a useful marker in detecting malignant behavior of pancreatic endocrine neoplasms. Oncology 2004;66: 468-75.
25. Li M, Zhang Y, Liu Z, Bharadwaj U, Wang H, Wang X, et al. Aberrant expression of zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progression. Proc Natl Acad Sci U S A 2007;104: 18636-41.
26. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Res 2004;14: 1902-10.
27. Cullen BR. Transcription and processing of human microRNA precursors. Mol Cell 2004;16: 861-5.
28. Qiu Y, Tomita Y, Zhang B, Nakamichi I, Morii E, Aozasa K. Pre-B-cell leukemia transcription factor 1 regulates expression of valosin-containing protein, a gene involved in cancer growth. Am J Pathol 2007;170: 152-9.
29. Tay Y, Zhang J, Thomson AM, Lim B, Rigoutsos I. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 2008;455: 1124-8.
30. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1999;1: 50-62.
31. Iwamura T, Caffrey TC, Kitamura N,Yamanari H, Setoguchi T,Hollingsworth MA. P-selectin expression in a metastatic pancreatic tumor cell line (SUIT-2). Cancer Res 1997;57: 1206-12.
32. Park JT, Shih Ie M, Wang TL. Identification of Pbx1, a potential oncogene, as a Notch3 target gene in ovarian cancer. Cancer Res 2008;68: 8852-60.
33. Tsujimoto Y, Tomita Y, Hoshida Y, Kono T, Oka T, Yamamoto S, et al. Elevated expression of valosin-containing protein (p97) is associated with poor prognosis of prostate cancer. Clin Cancer Res 2004;10: 3007-12.
34. Yamamoto S, Tomita Y,Hoshida Y, Iizuka N,Kidogami S, Miyata H, et al. Expression level of valosin-containing protein (p97) is associated with prognosis of esophageal carcinoma. ClinCancer Res 2004;10: 5558-65.
35. Yamamoto S, Tomita Y, Hoshida Y, Sakon M, Kameyama M, Imaoka S, et al. Expression of valosin-containing protein in colorectal carcinomas as a predictor for disease recurrence and prognosis. Clin Cancer Res 2004;10: 651-7.
36. Yamamoto S, Tomita Y, Hoshida Y, Toyosawa S, Inohara H, Kishino M, et al. Expression level of valosin-containing protein (VCP) as a prognostic marker for gingival squamous cell carcinoma. Ann Oncol 2004;15: 1432-8.
37. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005;7: 469-83.